

**Supporting Information**

**Parallel Synthesis of Oligonucleotides**

**Containing N-Acyl amino-LNA and Their Therapeutic Effects as Anti-microRNAs**

Tomo Takegawa-Araki,<sup>a\*</sup> Kai Yasukawa,<sup>a</sup> Norihiko Iwazaki,<sup>a</sup> Hideto Maruyama,<sup>a</sup> Hiroyuki Furukawa,<sup>a</sup> Hiroaki Sawamoto<sup>a</sup>


Satoshi Obika<sup>b</sup>

**Contents**



<sup>1</sup> H, <sup>13</sup> C, <sup>31</sup> P-NMR and high resolution mass spectra of synthesized compounds -----	p.1
All sequence data (Table S1) -----	
p.33	
RP-HPLC purification condition of oligonucleotides -----	p.35
RP-HPLC analysis condition of oligonucleotides -----	p.35
HPLC charts of oligonucleotides -----	
p.35	
Mass charts of oligonucleotides -----	
p.49	
LCMS analysis condition of oligonucleotides -----	
p.64	
Examples of profiles of LC-MS analysis (Fig. S1) -----	p.65
Representative UV melting curves (Fig. S2, Table S2, Fig. S3) -----	
p.66	


**1. <sup>1</sup>H, <sup>13</sup>C and <sup>31</sup>P-NMR spectra of synthesized compounds**

**1-[(1R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidine-2,4-dione (T-2a)**



<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **T-2a**







Elemental composition search on mass 666.20638

m/z=	661.20638-671.20638			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
666.20638	666.20687	-0.74	19.5	C <sub>34</sub> H <sub>31</sub> O <sub>8</sub> N <sub>3</sub> F <sub>3</sub>


**N-[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]purin-6-yl]benzamide (A<sup>bz</sup>-2a)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of A<sup>bz</sup>-2a



<sup>13</sup>C NMR (101 MHz, CHLOROFORM-d) of A<sup>bz</sup>-2a



High resolution mass spectra of A<sup>bz</sup>-2a




Elemental composition search on mass 779.24414


m/z = 774.24414–784.24414

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
779.24414	779.24466	-0.66	26.5	C <sub>41</sub> H <sub>34</sub> O <sub>7</sub> N <sub>6</sub> F <sub>3</sub>


[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-2-(2-methylpropanoylamino)purin-6-yl] N,N-diphenylcarbamate (**G<sup>dpc, ibu-2a</sup>**)




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **G<sup>dpc, ibu-2a</sup>**



$^{13}\text{C}$  NMR (101 MHz, CHLOROFORM-d) of  $\mathbf{G}^{\text{dpc, ibu-2a}}$




High resolution mass spectra of  $\mathbf{G}^{\text{dpc, ibu-2a}}$




Elemental composition search on mass 956.32370

m/z=	951.32370-961.32370			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
956.32370	956.32363	0.07	31.5	C <sub>51</sub> H <sub>45</sub> O <sub>9</sub> N <sub>7</sub> F <sub>3</sub>


**N-[1-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (**mC<sup>bz</sup>-2a**)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **mC<sup>bz</sup>-2a**



$^{13}\text{C}$  NMR (101 MHz, CHLOROFORM-d) of **mC<sup>bz</sup>-2a**




High resolution mass spectra of **mC<sup>bz</sup>-2a**





Elemental composition search on mass 769.24798

m/z=	764.24798-774.24798			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
769.24798	769.24907	-1.42	24.5	C <sub>41</sub> H <sub>36</sub> O <sub>8</sub> N <sub>4</sub> F <sub>3</sub>


**1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-pyrimidine-2,4-dione (T-2b)**



<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **T-2b**




High resolution mass spectra of T-2b




Elemental composition search on mass 584.24027

m/z= 579.24027-589.24027				
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
584.24027	584.24022	0.08	18.5	C <sub>33</sub> H <sub>34</sub> O <sub>7</sub> N <sub>3</sub>


**N-[9-[(1R,3R,4R,7S)-1-[[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]purin-6-yl]benzamide (A<sup>bz</sup>-2b)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of A<sup>bz</sup>-2b



<sup>1</sup>H NMR (101 MHz, CHLOROFORM-d) of A<sup>bz</sup>-2b




High resolution mass spectra of A<sup>bz</sup>-2b




Elemental composition search on mass 697.27695

m/z= 692.27695-702.27695				
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
697.27695	697.27801	-1.51	25.5	C <sub>40</sub> H <sub>37</sub> O <sub>6</sub> N <sub>6</sub>


[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-2-(2-methylpropanoylamino)purin-6-yl] *N,N*-diphenylcarbamate (**G<sup>dpc, ibu-2b</sup>**)



<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **G<sup>dpc, ibu-2b</sup>**



High resolution mass spectra of **G<sup>dpc</sup>, ibu-2b**




Elemental composition search on mass 874.35678


m/z= 869.35678-879.35678

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
874.35678	874.35698	-0.23	30.5	C <sub>50</sub> H <sub>48</sub> O <sub>8</sub> N <sub>7</sub>


**N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-hydroxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (mC<sup>bz</sup>-2b)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of mC<sup>bz</sup>-2b



$^{13}\text{C}$  NMR (101 MHz, CHLOROFORM-d) of **mC<sup>bz</sup>-2b**




High resolution mass spectra of **mC<sup>bz</sup>-2b**




Elemental composition search on mass 689.29778

m/z = 684.29778-694.29778				
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
689.29778	689.29698	1.17	22.5	C <sub>40</sub> H <sub>41</sub> O <sub>7</sub> N <sub>4</sub>


3-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-7-yl]oxy-(diisopropylamino)phosphanyl]oxypropanenitrile (**T-3a**)




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **T-3a**



<sup>31</sup>P NMR (162 MHz, CHLOROFORM-d) of **T-3a**



## High resolution mass spectra of T-3a




Elemental composition search on mass 868.33024


m/z = 863.33024–873.33024

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
868.33024	868.32928	1.11	20.5	C <sub>43</sub> H <sub>50</sub> O <sub>9</sub> N <sub>5</sub> F <sub>3</sub> P


**N-[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]purin-6-yl]benzamide (**A<sup>bz</sup>-3a**)**



<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **A<sup>bz</sup>-3a**




High resolution mass spectra of A<sup>bz</sup>-3a




Elemental composition search on mass 981.36782

m/z=	976.36782-986.36782			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
981.36782	981.36706	0.78	27.5	C <sub>50</sub> H <sub>53</sub> O <sub>8</sub> N <sub>8</sub> F <sub>3</sub> P


[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-2-(2-methylpropanoylamino)purin-6-yl] *N,N*-diphenylcarbamate (**G**<sup>dpc, ibu</sup>-**3a**)




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **G**<sup>dpc, ibu</sup>-**3a**



<sup>31</sup>P NMR (162 MHz, CHLOROFORM-d) of G<sup>dpc</sup>,ibu-3a



High resolution mass spectra of G<sup>dpc</sup>,ibu-3a




Elemental composition search on mass 1158.44859


m/z= 1153.44859-1163.44859

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
1158.44859	1158.44604	2.20	32.5	C <sub>60</sub> H <sub>64</sub> O <sub>10</sub> N <sub>9</sub> F <sub>3</sub> P


**N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-(2,2,2-trifluoroacetyl)-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (mC<sup>bz</sup>-3a)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of mC<sup>bz</sup>-3a



<sup>31</sup>P NMR (162 MHz, CHLOROFORM-d) of mC<sup>bz</sup>-3a



High resolution mass spectra of mC<sup>bz</sup>-3a




Elemental composition search on mass 971.37274


m/z = 966.37274–976.37274

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
971.37274	971.37147	1.30	25.5	C <sub>50</sub> H <sub>55</sub> O <sub>9</sub> N <sub>6</sub> F <sub>3</sub> P


3-[[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-5-methyl-3-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptan-7-yl]oxy-(diisopropylamino)phosphanyl]oxypropanenitrile (**T-3b**)




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **T-3b**



<sup>31</sup>P NMR (162 MHz, CHLOROFORM-d) of T-3b




High resolution mass spectra of T-3b




Elemental composition search on mass 786.36360

m/z=	781.36360-791.36360			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
786.36360	786.36263	1.24	19.5	C <sub>42</sub> H <sub>53</sub> O <sub>8</sub> N <sub>5</sub> P


**N-[9-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]purin-6-yl]benzamide (A<sup>bz</sup>-3b)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of A<sup>bz</sup>-3b



$^1\text{H}$  NMR (162 MHz, CHLOROFORM-d) of **A<sup>bz</sup>-3b**




High resolution mass spectra of **A<sup>bz</sup>-3b**




Elemental composition search on mass 897.38550

m/z=	892.38550-902.38550			
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
897.38550	897.38586	-0.40	27.5	C <sub>49</sub> H <sub>54</sub> O <sub>7</sub> N <sub>8</sub> P


[9-[(1*R*,3*R*,4*R*,7*S*)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-2-(2-methylpropanoylamino)purin-6-yl] *N,N*-diphenylcarbamate (**G<sup>dpc, ibu-3b</sup>**)



<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of **G<sup>dpc, ibu-3b</sup>**




High resolution mass spectra of  $\mathbf{G}^{\text{dpc, ibu-3b}}$




Elemental composition search on mass 1076.48116

m/z= 1071.48116-1081.48116				
m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
1076.48116	1076.48048	0.63	31.5	C <sub>59</sub> H <sub>67</sub> O <sub>9</sub> N <sub>9</sub> P

**N-[1-[(1R,3R,4R,7S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-7-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-5-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxo-pyrimidin-4-yl]benzamide (mC<sup>bz</sup>-3b)**




<sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) of mC<sup>bz</sup>-3b



<sup>31</sup>P NMR (162 MHz, CHLOROFORM-d) of **mC<sup>bz</sup>-3b**

High resolution mass spectra of **mC<sup>bz</sup>-3b**



Elemental composition search on mass 887.39007

m/z = 882.39007–892.39007

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
887.39007	887.39027	-0.23	25.5	C <sub>49</sub> H <sub>56</sub> O <sub>8</sub> N <sub>6</sub> P

**Table S1. All new sequence data**

SEQ ID	Sequence (5' to 3')	Modification	MS		Yield (%)	Synthesis	HPLC Purity (UV %)	HPLC Retention Time (min)
			Calcd.	Found.				
<b>ON-1(DNA)</b>	GTGTT <u>T</u> TTTGCT	DNA/all PO	3633.4	3630.9	—	solid phase	98.9	9.4
<b>ON-2(LNA)</b>	GTGTT <u>T</u> TTTGCT	LNA	3661.4	3661.4	—	solid phase	98.5	9.3
<b>ON-1a</b>	GTGTT <u>T</u> TTTGCT	ALNA[H]	3660.4	3660.5	55	solid phase	100.0	15.2
<b>ON-1b</b>	GTGTT <u>T</u> TTTGCT	ALNA[Me]	3674.4	3675.8	18	solid phase	100.0	15.3
<b>ON-1c</b>	GTGTT <u>T</u> TTTGCT	ALNA[formyl]	3688.4	3687.6	95	PEM	99.1	12.7
<b>ON-1d</b>	GTGTT <u>T</u> TTTGCT	ALNA[Ac]	3702.4	3701.6	102	PEM	100.0	15.4

<b>ON-1e</b>	GTGTT <u>T</u> TTTGCT	ALNA[Bz]	3764.5	3763.6	101	PEM	97.0	10
<b>ON-2(LNA)</b>	TTTTTTTT <u>T</u>	LNA	3008.0	3007.9	—	solid phase	93.6	12.2
<b>ON-2a</b>	TTTTTTTT <u>T</u>	ALNA[H]	3007.0	3006.2	20	solid phase	94.7	12.1
<b>ON-2b</b>	TTTTTTTT <u>T</u>	ALNA[Me]	3021.0	3020.7	21	solid phase	96.6	12.2
<b>ON-2c</b>	TTTTTTTT <u>T</u>	ALNA[formyl]	3035.0	3034.3	94	PEM	93.8	12.3
<b>ON-2d</b>	TTTTTTTT <u>T</u>	ALNA[Ac]	3049.0	3048.4	97	PEM	95.1	14.8
<b>ON-2e</b>	TTTTTTTT <u>T</u>	ALNA[Bz]	3111.1	3110.5	103	PEM	95.6	12.8
<b>ON-3a</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[H]	6288.2	6287.3	22	solid phase	97.8	14.9
<b>ON-3b</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Me]	6386.4	6385.4	16	solid phase	98.6	15.2
<b>ON-3d</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Ac]	6582.4	6581.5	98	PEM	97.2	15.2
<b>ON-4a</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[H]	6301.2	6300.7	19	solid phase	98.4	14.8
<b>ON-4b</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Me]	6413.4	6412.8	34	solid phase	91.9	15.1
<b>ON-4d</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Ac]	6637.5	6637.6	96	PEM	89.5	15.2
<b>ON-5a</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[H]	6343.3	6342.0	20	solid phase	97.2	14.8
<b>ON-5b</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Me]	6455.5	6454.6	14	solid phase	98.3	15.1
<b>ON-5d</b>	<u>AACATCAGTCTGATAAGCT</u>	ALNA[Ac]	6679.6	6678.8	96	PEM	95.7	15.2
<b>ON-6a</b>	<b>A<u>CAGTCTGATAAGCTA</u></b>	ALNA[H]/MOE	6424.4	6424.1	22	solid phase	100.0	15.3
<b>ON-6b</b>	<b>A<u>CAGTCTGATAAGCTA</u></b>	ALNA[Me]/MOE	6494.5	6492.4	14	solid phase	100.0	18.3
<b>ON-6c</b>	<b>A<u>CAGTCTGATAAGCTA</u></b>	ALNA[formyl]/MOE	6564.4	6563.7	97	PEM	99.1	15.5
<b>ON-6d</b>	<b>A<u>CAGTCTGATAAGCTA</u></b>	ALNA[Ac]/MOE	6634.6	6634.3	95	PEM	100.0	18.2
<b>ON-6e</b>	<b>A<u>CAGTCTGATAAGCTA</u></b>	ALNA[Bz]/MOE	6944.9	6939.6	99	PEM	100.0	13.8

Capital letters in the sequences refer to DNA (black), 2'-MOE (bold) and modified-amino-LNAs (underline, C denote methylcytosine). All phosphodiester linkages of **ON-3** to **ON-6** were replaced by phosphorothioate (PS) linkages.

#### RP-HPLC purification condition

Mobile phase A: 20 mM Hexylamine acetate in water

Mobile phase B: Acetonitrile

Gradient condition: 10-50% in 40 min

Flow rate: 4 mL/min

Column: Waters XBridge™ Oligonucleotide BEH C18 OBDM Prep Column, 130Å 2.5 µm (10 × 50 mm)

Column oven temperature: 60 °C

Detector: UV 260 nm

#### **RP-HPLC analysis conditions**

##### **ON-1 (DNA) and ON-1 (LNA) (purchased from GeneDesign)**

Mobile phase A: 100 mM HFIP / 8mM TEA in water

Mobile phase B: Methanol

gradient condition: 5-20 % (20min)

Flow rate: 1 mL/min

Column: Waters XBridge™ BEH C18 2.5 µm (4.6 × 75 mm)

Column oven temperature: 60 °C

Detector: UV 260 nm

#### **ON1a~ON-6e**

Mobile phase A: 20 mM Hexylamine acetate in water

Mobile phase B: Acetonitrile

Flow rate: 1 mL/min

Column: Waters XBridge™ BEH C18 130Å 2.5 µm (4.6 × 50 mm)


Column oven temperature: 60 °C

Detector: UV 260 nm

#### **HPLC charts of oligonucleotides**


##### **ON-1 (DNA) (purchased from GeneDesign)**

**HPLC (gradient condition: B% 5-20 % in 20 min)**




**ON-1 (LNA) (purchased from GeneDesign)**

**HPLC (gradient condition: B% 5-20 % in 20 min)**




**ON-1a**

**HPLC (gradient condition: B% 5-50 % in 22.5 min, then 100% in 5 min)**




### ON-1b

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




### ON-1c

HPLC (gradient condition: B% 5-50 % in 22.5 min, then 100% in 5 min)




#### ON-1d

HPLC (gradient condition: B% 10-65 % in 18 min, then 100% in 5 min)




#### ON-1e

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-2 (LNA)

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-2a

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




**ON-2b**

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




**ON-2c**

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




**ON-2d**

**HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)**




**ON-2e**

**HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)**




**ON-3a**

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




**ON-3b**

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-3d

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-4a

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




#### ON-4b

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




#### ON-4d

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




### ON-5a

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




### ON-5b

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-5d

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




ON-6a

HPLC (gradient condition: B% 5-50 % in 22.5 min, then 100% in 5 min)




### ON-6b

HPLC (gradient condition: B% 5-50 % in 22.5 min, then 100% in 5 min)




### ON-6c

HPLC (gradient condition: B% 10-50 % in 20 min, then 100% in 3 min)




**ON-6d**

**HPLC (gradient condition: B% 5-50 % in 22.5 min, then 100% in 5 min)**




**ON-6e**


**HPLC (gradient condition: B% 5-60 % in 22.5 min, then 100% in 5 min)**




**Mass chart of ON-1 (DNA)\* (MALDI-TOF, Bulker) \* purchased from Gene Design**




**Mass chart of ON-1 (LNA)\* (MALDI-TOF, Bulker) \*purchased from Gene Design**




**Mass chart of ON-1a (Q-Tof, Xevo G2-XS System, Waters)**




**Mass chart of ON-1b (ESI, ZQ mass detector, Waters)**




**Mass chart of ON-1c (Q-Tof, Xevo G2-XS System, Waters)**




Mass chart of ON-1d (Q-ToF, Xevo G2-XS System, Waters)




**Mass chart of ON-1e (Q-Tof, Xevo G2-XS System, Waters)**




**Mass chart of ON-2(LNA) (ESI, ZQ mass detector, Waters)**




**Mass chart of ON-2a (Q-Tof, Xevo G2-XS System, Waters)**




**Mass chart of ON-2b (ESI, ZQ mass detector, Waters)**




**Mass chart of ON-2c (Q-Tof, Xevo G2-XS System, Waters)**




**Mass chart of ON-2d (Q-Tof, Xevo G2-XS System, Waters)**





**Mass chart of ON-2e (Q-Tof, Xevo G2-XS System, Waters)**






Mass chart of ON-3a (Q-ToF, Xevo G2-XS System, Waters)




Mass chart of ON-3b (Q-ToF, Xevo G2-XS System, Waters)









Mass chart of ON-5a (Q-ToF, Xevo G2-XS System, Waters)




**Mass chart of ON-5b (Q-ToF, Xevo G2-XS System, Waters)**




**Mass chart of ON-5d (Q-ToF, Xevo G2-XS System, Waters)**




**Mass chart of ON-6a (Q-ToF, Xevo G2-XS System, Waters)**




**Mass chart of ON-6b (ESI, ZQ mass detector, Waters)**




**Mass chart of ON-6c (Q-Tof, Xevo G2-XS System, Waters)**



**Mass chart of ON-6d (Q-Tof, Xevo G2-XS System, Waters)**



**Mass chart of ON-6e (ESI, ZQ mass detector, Waters)**



#### LCMS analysis condition

Waters ZQ mass detector (ESI)

Mobile phase A: 400 mM HFIP / 15mM TEA in water

Mobile phase B: Methanol

Flow rate: 0.2 mL/min


Gradient condition: 20-30 % in 2.5 min

Column: Waters XBridge™ BEH C18 1.7  $\mu$ m (2.1  $\times$  100 mm)


Column oven temperature: 60 °C

Detector: UV 260 nm


(a) T =ALNA[H], RT =5.33 min




(b) T =ALNA[formyl], RT = 4.92 min




(c) T =ALNA[Ac], RT = 5.23 min



(d) T =ALNA[Bz], RT = 5.91 min




**Fig. S1 Examples of profiles of LC-MS analysis.** (a) LCMS analysis chart of **ON-1a** after solid-phase synthesis and HPLC purification (Sequence: 5'- GTGTTTTTTGCT -3', Capital letters = DNA, underline T = ALNA[H]). (b) LCMS chart of reaction mixture of formylation of **ON-1a** after 2 hours. (c) LCMS chart of reaction mixture of acetylation of **ON-1a** after 2 hours. (d) LCMS chart of reaction mixture of benzoylation of **ON-1a** after 2 hours. In all charts, the retention time (RT) around 0.78 min is the effect of injection or the peak of the reaction reagent. In reactions of **b-d**, the starting material **ON-1a** disappeared and converged to the target compounds. All the peaks were detected at 260 nm and ESI-MS (negative mode). We measured similar data on the PEM reaction of other oligonucleotides to confirm the progress of the reaction.



**Fig. S2** Representative UV melting curves of ON-1.

**Table. S2**  $T_m$  values were calculated as the average of three independent experiments for each sequence.

Seq No.	Ct (umol/L)	$T_m$ [°C] toward ssRNA 5'-r(UAGCUUAUCAGACUGAUGUUGA)-3'	SD	SEM
<b>ON-3d</b>	2	65.8	0.1	0.0
<b>ON-4d</b>	2	69.9	0.2	0.1
<b>ON-5d</b>	2	73.0	0.3	0.2



**Fig. S3** Representative UV melting curves of **ON-3d**, **ON-4d** and **ON-5d**